However, recently published data have suggested that IVI of anti-VEGF may result in systemic absorption and leads to a further reduction in plasma VEGF activity, which in turn leads to accelerated hypertension, worsening proteinuria, glomerular disease, thrombotic microangiopathy, and possible chronic renal function decline [5,6]. The gene discussed is VEGFA; the disease is glomerular disorder.